Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19)
Terry Cheuk‐Fung Yip, Grace Lui, Mandy Sze-Man Lai, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e26-e33
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 411
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study
Neil Krishan Aggarwal, Kyle C. Molina, Laurel Beaty, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 696-705
Open Access | Times Cited: 103
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 95
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
Joseph A. Lewnard, John M. McLaughlin, Deborah E. Malden, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 7, pp. 806-815
Open Access | Times Cited: 91
Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19
Kevin L. Schwartz, Jun Wang, Mina Tadrous, et al.
Canadian Medical Association Journal (2023) Vol. 195, Iss. 6, pp. E220-E226
Open Access | Times Cited: 82
Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 6, pp. 807-816
Open Access | Times Cited: 77
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
Qian Zheng, Pengfei Ma, Mingwei Wang, et al.
Journal of Infection (2022) Vol. 86, Iss. 1, pp. 66-117
Open Access | Times Cited: 75
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
Karolina Akinosoglou, Georgios Schinas, Charalambos Gogos
Viruses (2022) Vol. 14, Iss. 11, pp. 2540-2540
Open Access | Times Cited: 55
Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 47
Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Mandy Sze‐Man Lai, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2245086-e2245086
Open Access | Times Cited: 42
Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Huzaifa Ahmad Cheema, Uzair Jafar, Aruba Sohail, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 41
Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Anna Hoi Ying Mok, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 4, pp. 505-514
Open Access | Times Cited: 35
Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Fangyuan Tian, Zhaoyan Chen, Qiyi Feng
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 31
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
Effectiveness of Nirmatrelvir–Ritonavir Against the Development of Post–COVID-19 Conditions Among U.S. Veterans
George N. Ioannou, Kristin Berry, Nallakkandi Rajeevan, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 11, pp. 1486-1497
Open Access | Times Cited: 28
Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk
Dimitrios Paraskevis, Maria Gkova, Kassiani Μellou, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 12, pp. 1667-1674
Open Access | Times Cited: 27
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission
Liang En Wee, An Ting Tay, Calvin J. Chiew, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 10, pp. 1328-1333
Open Access | Times Cited: 26
Efectividad y seguridad de nirmatrelvir + ritonavir en la Covid-19. Estudio NiRCoV
V M González-Rodríguez, M J Hernández-Arroyo, C Rodríguez-Barrueco, et al.
Medicina de Familia SEMERGEN (2025) Vol. 51, Iss. 6, pp. 102462-102462
Open Access | Times Cited: 1
Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study)
Ivan Gentile, Riccardo Scotto, Maria Michela Scirocco, et al.
Microorganisms (2025) Vol. 13, Iss. 3, pp. 669-669
Open Access | Times Cited: 1
HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment
Dimitris Basoulis, Elpida Mastrogianni, Pantazis-Michail Voutsinas, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 577-577
Open Access | Times Cited: 19
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 19
Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis
Chienhsiu Huang, Tsung-Lung Lu, Lichen Lin
Antibiotics (2023) Vol. 12, Iss. 2, pp. 393-393
Open Access | Times Cited: 18
Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019–Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada
Jean‐Luc Kaboré, Benoît Laffont, Mamadou Diop, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 6, pp. 805-815
Open Access | Times Cited: 18
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong
David Tak Wai Lui, Matthew S. H. Chung, Eric H. Y. Lau, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2314393-e2314393
Open Access | Times Cited: 18
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 112-112
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top